TY - JOUR
T1 - CyTOF profiling of bone marrow immune dynamics across myeloma stages
AU - Cholujova, Dana
AU - Beke, Gabor
AU - Klucar, Lubos
AU - Drgona, Lubos
AU - Valuskova, Zuzana
AU - Leiba, Merav
AU - Kastritis, Efstathios
AU - Dorfman, David M.
AU - Anderson, Kenneth C.
AU - Jakubikova, Jana
N1 - Publisher Copyright:
© 2025 The Author(s). Published with license by Taylor & Francis Group, LLC.
PY - 2025/1/1
Y1 - 2025/1/1
N2 - Multiple myeloma (MM) orchestrates a profound disruption of immune balance within the bone marrow (BM) microenvironment, driving disease progression and therapeutic resistance. To better understand these complex immune dynamics, we used high-dimensional mass cytometry (CyTOF) profiling to comprehensively characterize the immune landscape of the BM across different stages of myeloma progression, including MGUS (n = 16), smoldering MM (SMM; n = 25), and active MM, both newly diagnosed (n = 43) and relapsed/refractory (n = 104). Our analysis revealed substantial immune remodeling during disease progression, characterized by adaptive immune suppression and extensive infiltration of innate immune populations. Transformation from MGUS to SMM was marked by significant alterations in central and effector memory T helper cells, effector cytotoxic T cells, and an enrichment of monocytic and neutrophil subsets. Active MM stages were further distinguished by increased expansion of myeloid and monocytic lineages, alongside a pronounced reduction in progenitor and transitional B cells. Correspondence analysis demonstrated that specific immune profiles were significantly associated with clinical outcomes, including progression-free survival and overall survival. This study highlights the potential of CyTOF-based molecular profiling to unravel the intricate immune dynamics of the BM microenvironment across MM disease stages, enhancing our understanding of MM pathogenesis and providing a foundation for identifying prognostic biomarkers and tailoring precision immunotherapeutic strategies.
AB - Multiple myeloma (MM) orchestrates a profound disruption of immune balance within the bone marrow (BM) microenvironment, driving disease progression and therapeutic resistance. To better understand these complex immune dynamics, we used high-dimensional mass cytometry (CyTOF) profiling to comprehensively characterize the immune landscape of the BM across different stages of myeloma progression, including MGUS (n = 16), smoldering MM (SMM; n = 25), and active MM, both newly diagnosed (n = 43) and relapsed/refractory (n = 104). Our analysis revealed substantial immune remodeling during disease progression, characterized by adaptive immune suppression and extensive infiltration of innate immune populations. Transformation from MGUS to SMM was marked by significant alterations in central and effector memory T helper cells, effector cytotoxic T cells, and an enrichment of monocytic and neutrophil subsets. Active MM stages were further distinguished by increased expansion of myeloid and monocytic lineages, alongside a pronounced reduction in progenitor and transitional B cells. Correspondence analysis demonstrated that specific immune profiles were significantly associated with clinical outcomes, including progression-free survival and overall survival. This study highlights the potential of CyTOF-based molecular profiling to unravel the intricate immune dynamics of the BM microenvironment across MM disease stages, enhancing our understanding of MM pathogenesis and providing a foundation for identifying prognostic biomarkers and tailoring precision immunotherapeutic strategies.
KW - Mass cytometry
KW - multiple myeloma
KW - tumor immune microenvironment
UR - https://www.scopus.com/pages/publications/105013585174
U2 - 10.1080/2162402X.2025.2542333
DO - 10.1080/2162402X.2025.2542333
M3 - Article
C2 - 40820826
AN - SCOPUS:105013585174
SN - 2162-4011
VL - 14
JO - OncoImmunology
JF - OncoImmunology
IS - 1
M1 - 2542333
ER -